Clinical trial Recruiting at 1 site Interventional Ages 18 and up Women only

Modulating brain regions to treat bladder issues in multiple sclerosis

Official title: A Randomized, Sham-Controlled Clinical Trial Evaluating Individualized Neuromodulation of Cortical Regions Involved in Neurogenic Overactive Bladder in Multiple Sclerosis

Run by The Methodist Hospital Research Institute · NCT06072703 · Data updated 2026-11-12

This study is testing whether a new brain stimulation technique can help women with multiple sclerosis who have bladder problems feel better by focusing on the brain instead of just the bladder.

Quick facts

Study typeInterventional
Ages18 Years and up
SexWomen only
Enrollment29 (estimated)
SponsorThe Methodist Hospital Research Institute
Academic / other
Drugs / interventionsradiation
Locations1 site (Houston, Texas)
StatusRecruiting
StartedOctober 30, 2023
Main results expectedDecember 31, 2027
Study endsDecember 31, 2027
Registry record updatedMarch 23, 2026
Trial IDNCT06072703 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adult women aged 18 and older with clinically stable multiple sclerosis and symptoms of neurogenic lower urinary tract dysfunction.

Probably not a fit

Patients who are pregnant, have a history of seizure disorders, or have specific urodynamic findings such as bladder outlet obstruction may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the use of repetitive transcranial magnetic stimulation (rTMS) to target brain regions involved in neurogenic overactive bladder (NOAB) in women with multiple sclerosis (MS). The study aims to shift the management of NOAB from a bladder-centric approach to a focus on brain restoration, utilizing noninvasive brain stimulation to improve urinary symptoms such as frequency and urgency. It is a randomized, double-blind, sham-controlled trial with an optional open-label extension phase, designed to evaluate the effectiveness of rTMS in enhancing brain connectivity and alleviating bladder dysfunction. Preliminary data suggest promising improvements in bladder symptoms without adverse effects.

Why it matters

Potential benefit: If successful, this approach could provide a less invasive and more effective treatment option for women with neurogenic bladder issues related to multiple sclerosis.

How similar studies have gone: While this approach is novel, preliminary data from related studies suggest potential success in improving bladder symptoms through brain modulation techniques.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adult women (≥ 18 years of age)
* Clinically stable MS defined as ExpandedDisability Status Score (EDSS) ≤ 7.5without exacerbation worsening in the preceding 6 months prior to study entry
* Neurogenic Lower Urinary Tract Dysfunction symptoms ≥ 3 months with NBSS total ≥ 15
* Individuals with Montreal Cognitive Assessment (MoCA) score \>10 will be eligible
* At least one bladder storage symptoms (e.g., urinary frequency, urinary urgency, nocturia with or without incontinence) indicated by OAB -AT≥ 8
* Individuals with active urinary tract infection (UTI) will be treated and will be enrolled after negative urinalysis

Exclusion Criteria:

* Pregnant/planning to become pregnant or nursing
* Urodynamic findings of bladder outlet obstruction
* Baclofen or other intrathecal pumps, Pacemakers.
* History of seizure disorder (SZ), immediate family of SZ disorder, in addition to individuals who are taking any medications such as (bupropion) Wellbutrin or substances (ex: heavy alcohol use) that would lower seizure threshold will be excluded.
* History of bipolar disorder, or individuals who are taking medications that can exacerbate the condition such as tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-nor-epinephrine reuptake inhibitors, anti-psychotics, lithium, bupropion (Wellbutrin) and antihistamines will be excluded.
* All intracranial lesions and hemorrhagic stroke will be excluded
* History of moderate to severe heart disease or unstable angina
* History of Autonomic Dysreflexia
* History of interstitial cystitis, pelvic radiation
* Intra-detrusor botulinumtoxinA (BTX-A) injection over the past 6 months
* Incarcerated patients will be excluded.
* Active sacral nerve stimulation (SNS) device or any other spinal stimulators
* Indwelling urethral or suprapubic catheter

Where it's running

  • Houston Methodist Hospital
    Houston, Texas, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.